S. Adams, R. J. Gray, S. Demaria, L. Goldstein, E. A. Perez et al., Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199, Journal of Clinical Oncology, vol.32, issue.27, pp.2959-2966, 2014.
DOI : 10.1200/JCO.2013.55.0491

H. R. Ali, E. Provenzano, S. Dawson, F. M. Blows, B. Liu et al., Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients, Ann. Oncol. Off. J, 2014.
DOI : 10.1093/annonc/mdu191

URL : https://academic.oup.com/annonc/article-pdf/25/8/1536/16703445/mdu191.pdf

H. R. Ali, A. Dariush, E. Provenzano, H. Bardwell, J. E. Abraham et al., Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer, Breast Cancer Research, vol.111, issue.51, 2016.
DOI : 10.1073/pnas.1415120112

L. Apetoh, F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz et al., Toll-like receptor 4???dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nature Medicine, vol.289, issue.9, 2007.
DOI : 10.4049/jimmunol.173.1.307

URL : https://hal.archives-ouvertes.fr/hal-00316924

H. D. Bear, S. Anderson, R. E. Smith, C. E. Geyer, E. P. Mamounas et al., Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27, J. Clin. Oncol, 2006.
DOI : 10.1200/jco.2005.04.1665

G. Bianchini, L. Pusztai, T. Pienkowski, Y. Im, G. V. Bianchi et al., Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial, Annals of Oncology, vol.26, pp.2429-2436, 2015.
DOI : 10.1093/annonc/mdv395

F. Binder-foucard, N. Bossard, P. Delafosse, A. Belot, A. Woronoff et al., and (Francim), the F. network of cancer registries (2014). Cancer incidence and mortality in France over the 1980?2012 period: Solid tumors

F. M. Blows, K. E. Driver, M. K. Schmidt, A. Broeks, F. E. Van-leeuwen et al., Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies, PLoS Medicine, vol.12, issue.5, 2010.
DOI : 10.1371/journal.pmed.1000279.s011

A. U. Buzdar, N. K. Ibrahim, D. Francis, D. J. Booser, E. S. Thomas et al., Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2???Positive Operable Breast Cancer, Journal of Clinical Oncology, vol.23, issue.16, pp.3676-3685, 2005.
DOI : 10.1200/JCO.2005.07.032

C. L. Carter, C. Allen, and D. E. Henson, Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer, vol.45, issue.1, pp.181-187, 1989.
DOI : 10.1038/bjc.1979.139

P. Cortazar, L. Zhang, M. Untch, K. Mehta, J. P. Costantino et al., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, The Lancet, vol.384, issue.9938, 2014.
DOI : 10.1016/S0140-6736(13)62422-8

C. Denkert, S. Loibl, A. Noske, M. Roller, B. M. Müller et al., Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer, Journal of Clinical Oncology, vol.28, issue.1, pp.105-113, 2010.
DOI : 10.1200/JCO.2009.23.7370

C. Denkert, G. Von-minckwitz, J. C. Brase, B. V. Sinn, S. Gade et al., Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2???Positive and Triple-Negative Primary Breast Cancers, Journal of Clinical Oncology, vol.33, issue.9, pp.983-991, 2015.
DOI : 10.1200/JCO.2014.58.1967

M. V. Dieci, C. Criscitiello, A. Goubar, G. Viale, P. Conte et al., Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study, Annals of Oncology, vol.25, issue.3, pp.611-618, 2014.
DOI : 10.1093/annonc/mdt556

M. V. Dieci, M. C. Mathieu, V. Guarneri, P. Conte, S. Delaloge et al., Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials, Annals of Oncology, vol.26, issue.8, 2015.
DOI : 10.1093/annonc/mdv239

G. P. Dunn, C. M. Koebel, and R. D. Schreiber, Interferons, immunity and cancer immunoediting, Nature Reviews Immunology, vol.313, issue.11, pp.836-848, 2006.
DOI : 10.4049/jimmunol.175.9.5586

B. Fisher, M. Bauer, D. L. Wickerham, C. K. Redmond, E. R. Fisher et al., Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update, Cancer, vol.152, issue.9, pp.1551-1557, 1983.
DOI : 10.1093/ajcp/65.4.439

B. Fisher, A. Brown, E. Mamounas, S. Wieand, A. Robidoux et al., Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18., Journal of Clinical Oncology, vol.15, issue.7, pp.2483-2493, 1997.
DOI : 10.1200/JCO.1997.15.7.2483

E. García-martínez, G. L. Gil, A. C. Benito, E. González-billalabeitia, M. A. Conesa et al., Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer, Breast Cancer Research, vol.109, issue.6, p.488, 2014.
DOI : 10.1073/pnas.1108781108

R. Gennari, S. Menard, F. Fagnoni, L. Ponchio, M. Scelsi et al., Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2, Clinical Cancer Research, vol.10, issue.17, pp.5650-5655, 2004.
DOI : 10.1158/1078-0432.CCR-04-0225

L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch et al., Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort, The Lancet, vol.375, issue.9712, pp.377-384, 2010.
DOI : 10.1016/S0140-6736(09)61964-4

L. Gianni, W. Eiermann, V. Semiglazov, A. Lluch, S. Tjulandin et al., Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort, The Lancet Oncology, vol.15, issue.6, pp.640-647, 2014.
DOI : 10.1016/S1470-2045(14)70080-4

J. L. Gnerlich, A. D. Deshpande, D. B. Jeffe, A. Sweet, N. White et al., Elevated Breast Cancer Mortality in Women Younger than Age 40 Years Compared with Older Women Is Attributed to Poorer Survival in Early-Stage Disease, Journal of the American College of Surgeons, vol.208, issue.3, 2009.
DOI : 10.1016/j.jamcollsurg.2008.12.001

M. Gobert, I. Treilleux, N. Bendriss-vermare, T. Bachelot, S. Goddard-leon et al., Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome, Cancer Research, vol.69, issue.5, 2000.
DOI : 10.1158/0008-5472.CAN-08-2360

URL : http://cancerres.aacrjournals.org/content/canres/69/5/2000.full.pdf

F. J. Gujam, J. J. Going, J. Edwards, Z. M. Mohammed, and D. C. Mcmillan, The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer, Critical Reviews in Oncology/Hematology, vol.89, issue.2, pp.231-241, 2014.
DOI : 10.1016/j.critrevonc.2013.08.014

A. Hamy-petit, L. Belin, H. Bonsang-kitzis, C. Paquet, J. Pierga et al., Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort, British Journal of Cancer, vol.8, issue.1, pp.44-52, 2016.
DOI : 10.1200/JCO.2006.09.2775

URL : http://www.nature.com/bjc/journal/v114/n1/pdf/bjc2015426a.pdf

N. Howlader, S. F. Altekruse, C. I. Li, V. W. Chen, C. A. Clarke et al., US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status, JNCI: Journal of the National Cancer Institute, vol.106, issue.5, 2014.
DOI : 10.1093/jnci/dju055

URL : https://academic.oup.com/jnci/article-pdf/106/5/dju055/17313523/dju055.pdf

I. Heppner, B. Untch, M. Denkert, C. Pfitzner, B. M. Lederer et al., Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant treated HER2- positive breast cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, 2016.

B. A. Kohler, R. L. Sherman, N. Howlader, A. Jemal, A. B. Ryerson et al., Annual Report to the Nation on the Status of Cancer, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J. Natl. Cancer Inst, p.48, 1975.

G. Kroemer, L. Senovilla, L. Galluzzi, F. André, and L. Zitvogel, Natural and therapy-induced immunosurveillance in breast cancer, Nature Medicine, vol.75, issue.10, pp.1128-1138, 2015.
DOI : 10.1038/nm.3773

H. M. Kuerer, L. A. Newman, T. L. Smith, F. C. Ames, K. K. Hunt et al., Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy, Journal of Clinical Oncology, vol.17, issue.2, pp.460-469, 1999.
DOI : 10.1200/JCO.1999.17.2.460

T. E. Kute, L. Savage, J. R. Stehle, J. W. Kim-shapiro, M. J. Blanks et al., Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing, Cancer Immunology, Immunotherapy, vol.309, issue.11, pp.1887-1896, 2009.
DOI : 10.1007/s00262-009-0700-0

S. Ladoire, G. Mignot, S. Dabakuyo, L. Arnould, L. Apetoh et al., In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival, The Journal of Pathology, vol.5, issue.3, pp.389-400, 2011.
DOI : 10.1038/nrc1613

S. Ladoire, L. Arnould, G. Mignot, L. Apetoh, C. Rébé et al., T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival, British Journal of Cancer, vol.23, issue.3, pp.366-371, 2011.
DOI : 10.1038/nri1936

URL : http://www.nature.com/bjc/journal/v105/n3/pdf/bjc2011261a.pdf

L. Atahan, I. Yildiz, F. Ozyigit, G. Sari, S. Gurkaynak et al., Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer, Acta Oncologica, vol.65, issue.1, pp.232-238, 2008.
DOI : 10.1016/j.ijrobp.2005.12.014

S. Liu, X. Duan, L. Xu, L. Xin, Y. Cheng et al., Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy, Breast Cancer Research and Treatment, vol.15, issue.2, pp.239-249, 2015.
DOI : 10.1016/S1470-2045(13)70477-7

S. Loi, S. Michiels, R. Salgado, N. Sirtaine, V. Jose et al., Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial, Annals of Oncology, vol.25, issue.8, pp.1544-1550, 2014.
DOI : 10.1093/annonc/mdu112

S. Mahmoud, A. Lee, I. Ellis, and A. Green, T lymphocytes infiltrating breast cancer, OncoImmunology, vol.58, issue.3, pp.364-365, 2012.
DOI : 10.1016/j.cell.2011.02.013

URL : http://www.tandfonline.com/doi/pdf/10.4161/onci.18614?needAccess=true

Y. Mao, Q. Qu, Y. Zhang, J. Liu, X. Chen et al., The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis, PLoS ONE, vol.73, issue.3, 2014.
DOI : 10.1371/journal.pone.0115103.s005

Y. Mao, Q. Qu, X. Chen, O. Huang, J. Wu et al., The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis, PLOS ONE, vol.26, issue.2, 2016.
DOI : 10.1371/journal.pone.0152500.s008

D. Mittal, M. M. Gubin, R. D. Schreiber, and M. J. Smyth, New insights into cancer immunoediting and its three component phases???elimination, equilibrium and escape, Current Opinion in Immunology, vol.27, pp.16-25, 2014.
DOI : 10.1016/j.coi.2014.01.004

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388310/pdf

S. Nagalla, J. W. Chou, M. C. Willingham, J. Ruiz, J. P. Vaughn et al., Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis, Genome Biology, vol.14, issue.4, p.34, 2013.
DOI : 10.1158/1078-0432.CCR-06-2765

URL : https://genomebiology.biomedcentral.com/track/pdf/10.1186/gb-2013-14-4-r34?site=genomebiology.biomedcentral.com

A. M. Neville, R. Bettelheim, R. D. Gelber, J. Säve-söderbergh, B. W. Davis et al., Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group., Journal of Clinical Oncology, vol.10, issue.5, pp.696-705, 1992.
DOI : 10.1200/JCO.1992.10.5.696

M. Ono, H. Tsuda, C. Shimizu, S. Yamamoto, T. Shibata et al., Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer, Breast Cancer Research and Treatment, vol.26, issue.10, pp.793-805, 2012.
DOI : 10.1080/07357900802098165

C. A. Parise, V. Caggiano, C. A. Parise, C. , and V. , Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers, Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers, J, 2014.

S. Park, Z. Jiang, E. D. Mortenson, L. Deng, O. Radkevich-brown et al., The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity, Cancer Cell, vol.18, issue.2, pp.160-170, 2010.
DOI : 10.1016/j.ccr.2010.06.014

E. A. Perez, E. H. Romond, V. J. Suman, J. Jeong, N. E. Davidson et al., Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2???Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31, Journal of Clinical Oncology, vol.29, issue.25, 2011.
DOI : 10.1200/JCO.2011.35.0868

E. A. Perez, K. V. Ballman, K. S. Tenner, E. A. Thompson, S. S. Badve et al., Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer, JAMA Oncology, vol.2, issue.1, pp.56-64, 2016.
DOI : 10.1001/jamaoncol.2015.3239

S. A. Perez, M. V. Karamouzis, D. V. Skarlos, A. Ardavanis, N. N. Sotiriadou et al., CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients, Clinical Cancer Research, vol.13, issue.9, pp.2714-2721, 2007.
DOI : 10.1158/1078-0432.CCR-06-2347

URL : http://clincancerres.aacrjournals.org/content/clincanres/13/9/2714.full.pdf

C. M. Perou, T. Sørlie, M. B. Eisen, M. Van-de-rijn, S. S. Jeffrey et al., Molecular portraits of human breast tumours, Nature, vol.406, issue.6797, pp.747-752, 2000.
DOI : 10.1038/35021093

P. Rastogi, S. J. Anderson, H. D. Bear, C. E. Geyer, M. S. Kahlenberg et al., Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27, Journal of Clinical Oncology, vol.26, issue.5, pp.778-785, 2008.
DOI : 10.1200/JCO.2007.15.0235

R. Rouzier, C. M. Perou, W. F. Symmans, N. Ibrahim, M. Cristofanilli et al., Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy, Clinical Cancer Research, vol.11, issue.16, 2005.
DOI : 10.1158/1078-0432.CCR-04-2421

URL : http://clincancerres.aacrjournals.org/content/clincanres/11/16/5678.full.pdf

P. Rovere-querini and A. Castiglioni, Adjuvant role for cell death during chemo- and radiotherapy of cancer?, Expert Review of Clinical Immunology, vol.14, issue.1, pp.27-32, 2008.
DOI : 10.1038/sj.cdd.4402148

R. Salgado, C. Denkert, S. Demaria, N. Sirtaine, F. Klauschen et al., The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014, Annals of Oncology, vol.26, issue.2, pp.259-271, 2015.
DOI : 10.1093/annonc/mdu450

R. Salgado, C. Denkert, C. Campbell, P. Savas, P. Nuciforo et al., Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab, JAMA Oncology, vol.1, issue.4, pp.448-454, 2015.
DOI : 10.1001/jamaoncol.2015.0830

URL : http://oncology.jamanetwork.com/data/journals/oncology/934193/coi150025.pdf

A. M. Schwartz, D. E. Henson, D. Chen, and S. And-rajamarthandan, Histologic Grade Remains a Prognostic Factor for Breast Cancer Regardless of the Number of Positive Lymph Nodes and Tumor Size: A Study of 161???708 Cases of Breast Cancer From the SEER Program, Archives of Pathology & Laboratory Medicine, vol.138, issue.8, pp.1048-1052, 2014.
DOI : 10.5858/arpa.2013-0435-OA

A. N. Seo, H. J. Lee, E. J. Kim, H. J. Kim, M. H. Jang et al., Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer, British Journal of Cancer, vol.177, issue.10, pp.2705-2713, 2013.
DOI : 10.1172/JCI35180

A. Sheri, I. E. Smith, S. R. Johnston, R. A-'hern, A. Nerurkar et al., Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy, Annals of Oncology, vol.26, issue.1, 2015.
DOI : 10.1093/annonc/mdu508

URL : https://academic.oup.com/annonc/article-pdf/26/1/75/19480983/mdu508.pdf

J. Shimizu, S. Yamazaki, and S. Sakaguchi, Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity, J. Immunol. Baltim. Md, vol.163, pp.5211-5218, 1950.

I. Smith, M. Procter, R. D. Gelber, S. Guillaume, A. Feyereislova et al., 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, The Lancet, vol.369, issue.9555, pp.29-36, 2007.
DOI : 10.1016/S0140-6736(07)60028-2

T. Sørlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc. Natl. Acad, 2001.
DOI : 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O

N. L. Spector and K. L. Blackwell, Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2???Positive Breast Cancer, Journal of Clinical Oncology, vol.27, issue.34, pp.5838-5847, 2009.
DOI : 10.1200/JCO.2009.22.1507

R. Stuart-harris, C. Caldas, S. E. Pinder, and P. Pharoah, Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients, The Breast, vol.17, issue.4, pp.323-334, 2008.
DOI : 10.1016/j.breast.2008.02.002

W. F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer et al., Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy, Journal of Clinical Oncology, vol.25, issue.28, 2007.
DOI : 10.1200/JCO.2007.10.6823

M. Untch, M. Rezai, S. Loibl, P. A. Fasching, J. Huober et al., Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study, Journal of Clinical Oncology, vol.28, issue.12, 2010.
DOI : 10.1200/JCO.2009.23.8451

V. Varadan, H. Gilmore, K. L. Miskimen, D. Tuck, S. Parsai et al., Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer, Clinical Cancer Research, vol.22, issue.13, 2016.
DOI : 10.1158/1078-0432.CCR-15-2021

URL : http://clincancerres.aacrjournals.org/content/clincanres/22/13/3249.full.pdf

N. R. West, S. E. Kost, S. D. Martin, K. Milne, R. J. Deleeuw et al., Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer, British Journal of Cancer, vol.5, issue.1, pp.155-162, 2013.
DOI : 10.1371/journal.pone.0014282

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553524/pdf

N. Wolmark, J. Wang, E. Mamounas, J. Bryant, and B. Fisher, Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18, JNCI Monographs, vol.2001, issue.30, pp.96-102, 2001.
DOI : 10.1093/oxfordjournals.jncimonographs.a003469